Syndax Pharmaceuticals SNDX Business Segments — Interest Income Expense Net

Similar metrics at other companies

AMP

AMPHPharmaceutical Products — Investment Income Interest

$2.4M+14.9%

VRTXPharmaceuticals — Interest income, net

$114.8M-2.6%

KNSAPharmaceutical — Investment Income Interest

$3.41M+49.1%

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Interest Income

$6.66M+276%

DNLITherapeutics Segment — Interest and other income, net

$8.91M-29.3%

ANABBiopharma Company — Interest Income Other

$2.33M-43.1%

Questions, answered.

What is Syndax Pharmaceuticals's business segments — interest income expense net?

Syndax Pharmaceuticals (SNDX) reported business segments — interest income expense net of -$3.56M in Q1 2026.

How has Syndax Pharmaceuticals's business segments — interest income expense net changed year-over-year?

Syndax Pharmaceuticals's business segments — interest income expense net increased by 50.4% year-over-year, from -$7.18M to -$3.56M.

What is the long-term trend for Syndax Pharmaceuticals's business segments — interest income expense net?

Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — interest income expense net has grown at a 58.2% compound annual growth rate (CAGR), from -$2.74M to -$10.83M.

What does business segments — interest income expense net mean?

This metric represents the net balance of interest income earned on cash and investment holdings offset by interest expenses incurred on debt obligations within the specific business segment. It reflects the segment's net financing cost or return on capital, providing insight into how the company manages its liquidity and capital structure to support ongoing research and development activities. Monitoring this balance helps investors understand the impact of financial leverage and treasury management on the segment's overall profitability.